In Morningstar’s recent ESG Industry Landscape Report: Biopharma, its analysts found that large drug manufacturers face moderate environmental, social and governance (ESG) risk exposure but have limited materiality to valuation. More specifically, access to basic services, product governance, and business ethics are the three most material ESG risks to pharma and biotech companies.
Access to basic services is potentially one of the most prominent ESG risks to biopharma firms, according to Morningstar’s report, where drug pricing complexity creates issues of affordability among end users. Very few people know the exact net prices any buyer pays after rebates and discounts. Determining the fairness of that price is even more complex.
Product governance is also a critical consideration of ESG risk given the very nature of drugs themselves. However, although legal costs are prevalent, the materiality of this ESG risk remains low given firms’ much larger profits.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze